This is a ready-to-use protocol for qualifying a cryoformulation and its cooling/thaw profile against the worst-case handling a product could realistically see across manufacturing, shipping, and clinical use, not just the single planned freeze and thaw in the primary process flow. Replace every <<FILL: ...>> placeholder with your own specifics and route it through your normal document control, review, and approval before execution. A worked filled specimen follows. Verify each cited reference against the current source before you rely on it.
Document control header
| Field | Entry |
|---|---|
| Document title | Freeze-Thaw Study Protocol for <<FILL: product / cell type>> |
| Document number | <<FILL: e.g. FTS-2026-02>> |
| Version | <<FILL>> |
| Effective date | <<FILL>> |
| Linked formulation development report | <<FILL: ref>> |
| Protocol owner | <<FILL: e.g. Formulation Development Lead>> |
1. Purpose
This protocol defines the worst-case freeze-thaw cycles, sampling, and acceptance criteria needed to demonstrate that the cryoformulation and cooling/thaw profile for <<FILL: product>> protects product quality and function across the range of handling the product could realistically encounter, not only the single cycle described in the primary manufacturing process flow.
2. Scope
| Dimension | Decision |
|---|---|
| Product / cell type in scope | <<FILL>> |
| Cryoformulation under study | <<FILL: cryoprotectant identity, concentration, buffer composition>> |
| Cooling and thaw methods under study | <<FILL: cooling rate/profile, thaw method and rate>> |
| Out of scope | <<FILL: e.g. long-term storage stability, covered under a separate stability protocol>> |
3. Responsibilities
| Role | Responsibility |
|---|---|
| Protocol author / formulation lead | Writes this protocol, defines the worst-case handling map, oversees execution |
| Manufacturing / process representative | Executes freeze and thaw cycles per the defined profiles |
| Analytical / potency assay lab | Performs viability, recovery, and functional potency testing per the sampling plan |
| Quality Assurance | Reviews and approves the protocol, dispositions deviations, approves the report |
4. Worst-case handling map
State every realistic handling scenario the product could see, not only the primary planned cycle. This map is the basis for the cycle design in section 5, and a study that skips a real handling scenario has not actually qualified the formulation against it.
| Scenario | Description | Included in study? |
|---|---|---|
| Primary planned cycle | One controlled freeze, one controlled thaw at the point of use | <<FILL: Yes/No, rationale if No>> |
| Delayed infusion / thaw-then-hold | Product thawed but administration delayed, requiring a hold or a second controlled freeze | <<FILL>> |
| Shipment interruption | A charged cryogenic shipper experiences a partial warming event before recharge and continued transit | <<FILL>> |
| Adjacent-unit thermal exposure | One container in a multi-vial or multi-aliquot lot is accessed while sibling containers remain nearby in the same rack or dewar | <<FILL>> |
<<FILL: any product- or program-specific scenario>> | <<FILL>> | <<FILL>> |
5. Cycle design
| Cycle | Purpose | Cooling profile | Hold condition / duration | Thaw method |
|---|---|---|---|---|
| Cycle 1 (baseline) | Primary planned single freeze-thaw | <<FILL>> | <<FILL>> | <<FILL>> |
| Cycle 2 | <<FILL: e.g. worst-case second freeze after a delayed-infusion scenario>> | <<FILL>> | <<FILL>> | <<FILL>> |
| Cycle 3 | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
State the number of cycles studied against the worst-case handling map in section 4, not against a stock number; ICH Q5C’s stress-testing expectations commonly support at least three cycles for a biologic drug substance generally, but the product’s own worst-case handling, not that number alone, should set how many cycles this study actually needs.
6. Sampling and readouts
Every cycle is read the same way, not just the immediate post-thaw count; a study that stops at an immediate viability number has not checked for the delayed-apoptosis failure mode described in the linked article.
| Readout | Method | Timepoint(s) | Acceptance criterion |
|---|---|---|---|
| Immediate post-thaw viability | <<FILL: e.g. dye-exclusion count>> | Immediately post-thaw | <<FILL>> |
| Post-thaw recovery | <<FILL>> | <<FILL: e.g. 4 and 24 hours post-thaw>> | <<FILL>> |
| Functional potency | <<FILL: assay specific to the product's mechanism of action>> | <<FILL>> | <<FILL>> |
| Identity / purity, if applicable | <<FILL>> | <<FILL>> | <<FILL>> |
7. Deviation handling
Any excursion from the defined cooling profile, hold condition, or thaw method, or any result outside an acceptance criterion in section 6, is recorded as a deviation per <<FILL: deviation SOP-ID>> at the point it is found, with root cause where determinable and an impact assessment on the cycle’s ability to support the study conclusion. Do not discard a cycle’s data without a documented, QA-approved rationale.
8. Data analysis and acceptance criteria for the study
State in advance how results will be analyzed: each readout compared against its acceptance criterion per cycle, with the study concluding only when every included cycle either met every acceptance criterion or, for a cycle deliberately designed to find the product’s tolerance limit, produced a result that clearly establishes where that limit sits. A single unexplained functional potency failure is not eligible for a passing conclusion regardless of viability results in the same cycle.
9. Report commitments
The protocol author issues a summary report on completion covering: cycle-by-cycle results against every readout, all deviations and their resolution, and an explicit conclusion on which handling scenarios from section 4 the qualified cryoformulation and cooling/thaw profile supports. QA approves the report before the formulation and cooling profile are released for use in GMP manufacturing.
10. References
ICH Q5C, Quality of Biotechnological Products: Stability Testing. ICH Q6B, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
Confirm the current version of each reference before issue.
11. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
12. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Formulation Development) | <<FILL>> | ||
| Reviewer (Manufacturing) | <<FILL>> | ||
| Reviewer (Analytical) | <<FILL>> | ||
| Approver (QA) | <<FILL>> |
Filled specimen
Extract for an example autologous CAR T-cell product, Acme Therapeutics’ ATX-CT7, DMSO-based cryoformulation.
| Field | Entry |
|---|---|
| Worst-case scenarios included | Primary planned cycle; delayed-infusion second freeze; shipment interruption with a 45-minute partial warming event before recharge |
| Cycle 2 design | Product thawed per the primary planned method, held at 2 to 8 degrees C for 2 hours to simulate a delayed infusion decision point, then re-frozen per the qualified cooling profile |
| Readouts | Dye-exclusion viability immediately post-thaw; recovery and dye-exclusion viability again at 4 and 24 hours post-thaw; a cytotoxicity-based functional potency assay at the 4-hour timepoint |
Results: Cycle 1 met all acceptance criteria. Cycle 2 (simulated delayed-infusion re-freeze) showed immediate post-thaw viability within acceptance, but functional potency at the 4-hour timepoint fell below the acceptance criterion, while viability alone remained acceptable. Conclusion: the primary planned single freeze-thaw is qualified; a second controlled freeze following a delayed-infusion scenario is not supported by this cryoformulation and cooling profile, and clinical site training was updated to reflect that the product cannot tolerate a second freeze once thawed.
The specimen shows exactly why the readout has to go past viability: a viability-only study would have called Cycle 2 acceptable, and the functional potency result is what actually caught the failure the delayed-apoptosis mechanism predicts.
Common inspection findings this protocol prevents
- A freeze-thaw study that qualifies only the single planned cycle, with no worst-case handling scenario studied or documented as out of scope with a stated rationale.
- A study concluding “product remained viable” with no functional potency readout, missing a failure mode a dye-exclusion count cannot detect.
- A cycle count set by convention, such as always using three, with no traceable connection to the product’s actual worst-case handling map.
- Thaw method treated as an afterthought relative to the freeze method, with no equivalent rigor applied to thaw rate, device, or post-thaw dilution.
- A cycle’s data discarded with no documented, QA-approved rationale.
How to adapt this protocol
- Set your document number, product, and linked formulation development report in the header.
- Build the worst-case handling map in section 4 from your product’s actual manufacturing, shipping, and clinical handling pathway, not a generic list.
- Design cycles in section 5 to test that map directly, and state the rationale for the cycle count chosen.
- Set acceptance criteria in section 6 for recovery and functional potency, not viability alone, at more than one post-thaw timepoint.
- Point section 7 to your real deviation SOP, and confirm every reference in section 10 against the current published version before issue.